OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

KRAS G12C is one of the most common oncogenic mutations in NSCLC. GDC-6036 is an oral, highly potent, and selective KRAS G12C inhibitor with robust tumor growth inhibition in multiple pre-clinical models. An open-label, Phase I dose-escalation/expansion study of GDC-6036 as monotherapy and in combination with other anticancer therapies is underway for patients (pts) with locally advanced or metastatic solid tumors harboring a KRAS G12C mutation. Data from GDC-6036 monotherapy in pts with NSCLC are presented herein.